Consistently, our previous investigations demonstrated that AMPK activators such as AICAR and Metformin inhibited both mTOR/p70S6K and AKT/ERK/FOXM1 signals in ovarian cancer cells and produced a synergistic effect on Cisplatin-induced cell cytotoxicity in ovarian cancer cells [35,36,37], suggesting that targeted therapies exert growth inhibition effect on ovarian cancer cells and improve the efficacy of Cisplatin-based chemotherapy in advanced ovarian cancer. This evidence concerns the gene FOXM1 and ovarian carcinoma.